比较首个化疗疗程前后 EQ-5D-5L 效用值和 EORTC QLQ-C30 项目得分，对比首个化疗前后 EORTC QLQ-C30 五个项目存在问题的患者比例，还基于副作用及其严重程度、焦虑程度对 QOL 进行比较。 结果：首个化疗疗程后，报告日常活动存在问题的患者数量显著增加。EORTC QLQ-C30 ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

CEL-SCI (CVM) announced new data has been published from its prior Phase 3 study of Multikine in newly diagnosed, treatment naive, resectable, ...

Quality of life (QoL) was assessed and validated through use of two instruments, EORTC QLQ-C30 and EORTC QLQ-H&N 35 across all clinical sites. EORTC QLQ-C30 is a 30-item questionnaire developed by ...

At week 21, LSMDs were 0.03 (95% CI, –0.05 to 0.11) for EQ-5D-5L, 0.98 (95% CI, –7.24 to 9.19) for EORTC QLQ-C30 GHS/QoL, and 1.59 (95% CI, –5.16 to 8.33) for EORTC QLQ-C30 PF (P ...

Table 2 displays the baseline QoL scores across the two categories of ... in scores from baseline to 3 months for all dimensions of EORTC QLQ-C30 instrument. On an average, they were small.